Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2019 Publisher: Zentiva Pharma UK Limited, 12 New Fetter Lane, London, EC4A 1JP, United Kingdom Trading as: Zentiva, 12 New Fetter Lane, London EC4A 1JP, UK
Valganciclovir 450 mg film-coated tablets.
| Pharmaceutical Form |
|---|
|
Film-coated tablet. Oval, biconvex, pink colored film-coated tablets approx16.83 × 7.95 mm. |
Each film-coated tablet contains 496.3 mg of valganciclovir hydrochloride equivalent to 450 mg of valganciclovir (as free base).
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Valganciclovir |
Valganciclovir is an L-valyl ester (prodrug) of ganciclovir. Ganciclovir is a synthetic analogue of 2'-deoxyguanosine and inhibits replication of herpes viruses in vitro and in vivo. |
| List of Excipients |
|---|
|
Tablet core: Povidone (K30) Tablet film-coat: Opadry Pink 15B24005 containing: Hypromellose (3cP, 6 cP) |
High density polyethylene (HDPE) bottles and child resistant polypropylene (PP) screw cap with induction heat sealing (with aluminum foil). The screw cap has a tamper evident.
Pack size: One bottle containing 60 film coated tablets.
Zentiva Pharma UK Limited, 12 New Fetter Lane, London, EC4A 1JP, United Kingdom
Trading as: Zentiva, 12 New Fetter Lane, London EC4A 1JP, UK
PL 17780/0688
22/10/2015
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
